TY - JOUR AU - Paula Rodríguez-Otero, AU - Bruno Paiva, AU - Monika Engelhardt, AU - Felipe Prósper, AU - Jesús F. San Miguel, PY - 2017/02/28 Y2 - 2024/03/28 TI - Is immunotherapy here to stay in multiple myeloma? JF - Haematologica JA - haematol VL - 102 IS - 3 SE - Review Articles DO - 10.3324/haematol.2016.152504 UR - https://haematologica.org/article/view/7994 SP - 423-432 AB - Immune escape and impaired immune surveillance have been identified as emerging hallmarks of cancer.1 Multiple myeloma represents a genuine example of disrupted immune surveillance characterized by: impaired antibody production, deregulation of the T and natural killer cell compartment, disruption of antigen presentation machinery, upregulation of inhibitory surface ligands, and recruitment of immunosuppressive cells. Although the potential value of immunotherapeutic interventions had a clear antecedent in the graft-versus-myeloma effect induced by allogeneic stem cell transplant and donor lymphocyte infusions, it is only recently that this field has faced a real revolution. In this review we discuss the current results obtained with immune approaches in patients with multiple myeloma that have placed this disease under the scope of immuno-oncology, bringing new therapeutic opportunities for the treatment of multiple myeloma patients. ER -